---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Care management intervention strategies"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Care management intervention strategies. Topics: Continuous glucose monitoring in insulinoma, Dietitian-led nutritional management and patient and family education in insulinoma, Multidisciplinary team and tumor board management, Multidisciplinary eligibility review and coordination of tumor-directed therapy during ersodetug treatment, and 2 further topics. 6 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Continuous glucose monitoring in insulinoma

> “A continuous glucose monitoring system can support patients in recognizing hypoglycemic events and prevent serious complications, especially during the night”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “A CGMS could be a very useful tool in patients with insulinoma to early recognise a hypoglycaemic event and prevent severe complications.”
> “Furthermore, it is also possible to connect an infusion pump automatically administering glucose as required.”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

> “Patients with insulinoma frequently have impaired hypoglycaemia awareness and evaluating treatment effect by symptoms alone may miss asymptomatic hypoglycaemia”
> “We advocate the use of continuous glucose monitoring in patients with insulinoma to reduce the incidence of severe hypoglycaemic episodes and enable dietary and medical intervention to be tailored for the individual and their lifestyle.”

Source: [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/)

<a id="topic-2.2.2.4-2"></a>

### Dietitian-led nutritional management and patient and family education in insulinoma

> “Early education on hypoglycaemia identification and treatment for the patient and their family is critical.”
> “Patients with insulinoma should have specialist dietitian assessment and follow up comprising regular assessment of glycaemic control, nutritional education and intervention.”

Source: [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/)

<a id="topic-2.2.2.4-3"></a>

### Multidisciplinary team and tumor board management

> “The management of patients with a functioning Pan-NET syndrome is complex due to its heterogeneous presentation and multisystem involvement.”
> “Consequently, work-up and treatment of a (suspected) functioning syndrome should preferably be performed in a multidisciplinary setting and discussed in expert tumour boards.”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

> “Early referral to a dedicated neuroendocrine multidisciplinary team is critical considering the array of medical, oncological, interventional radiological and nuclear medical options.”

Source: [Brown et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29205458/)

> “Overall, our findings support an individualized, multidisciplinary treatment strategy integrating endocrine, oncological, and interventional expertise.”

Source: [Guerrero-Pérez et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43000590/)

<a id="topic-2.2.2.4-4"></a>

### Multidisciplinary eligibility review and coordination of tumor-directed therapy during ersodetug treatment

> “The eligibility criteria of all participants must be evaluated by a multidisciplinary team led by the PI, which must include an oncologist”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

> “Individuals resumed tumor-directed therapies or procedures as deemed appropriate by the multidisciplinary clinical care team, and these interventions were systematically recorded as part of the observational dataset.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.2.4-5"></a>

### Monitoring for hypoglycemia flare during PRRT

> “Side-effects included G3/4 myelosuppression in 4/15 patients and hypoglycaemia flare (hospitalisation >48 h) in 7/15 patients.”
> “PRRT provides durable hypoglycaemic and oncologic disease control of MI with manageable toxicity including hypoglycaemia flare requiring multidisciplinary care.”

Source: [Pattison et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40424062/)

<a id="topic-2.2.2.4-6"></a>

### Palliative care coordination at the end of life in metastatic insulinoma

> “Hypoglycaemia is a common cause of death for patients with metastatic insulinoma, whose disease has progressed despite multiple lines of therapy.”
> “Declining oral intake, anxiety around symptoms of hypoglycaemia, complex emotions regarding the cessation of CGM and difficulty in managing other symptoms such as pain should be navigated together with palliative care clinicians”

Source: [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
